Additional diversity has previously been contributed by ADARs self‐editing their active DBDs, and thereby altering their function,19 and that result in changes in the deaminase “motifs” targeted.20 Such variants may exhibit the potential for alternative ADAR targeting preferences during tumour progression. The gene discussed is ADAR; the disease is neoplasm.